Kennedy, Kim R.; Turner, John Harvey; MacDonald, William B. G.; Claringbold, Phillip G.; Boardman, Glenn; Ransom, David T. published the artcile< Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy>, HPLC of Formula: 112-63-0, the main research area is lutetium octreotate anticancer agent radionuclide toxicity neuroendocrine tumor; myelodysplasia; neuroendocrine tumor; peptide receptor radionuclide therapy.
Peptide receptor radionuclide therapy (PRRT) has shown favorable results in neuroendocrine tumors (NETs). Long-term safety and efficacy data for 177Lu-octreotate PRRT, particularly in combination with chemotherapy, is lacking. The authors conducted a retrospective review of the long-term toxicity and survival outcomes of 104 patients with advanced NETs treated on 4 phase 2 clin. trials with Lutetium-177-octreotate (177Lu-octreotate) PRRT, mostly in combination with chemotherapy. Median follow-up was 68 mo, which represents the longest follow-up study of 177Lu-octreotate PRRT for NETs to date. Median progression-free survival (PFS) was 37 mo, and median overall survival (OS) was 71 mo. Five- and 10-yr OS were 62% and 29%, and 5- and 10-yr PFS were 36% and 21%, resp., demonstrating 177Lu-octreotate can provide durable responses. PRRT was well tolerated with 1.9% of patients developing chronic renal impairment and 1% of patients developing long-term thrombocytopenia. Interestingly, there was a relatively high rate of myelodysplasia (MDS)/leukemia (6.7%), possibly attributable to the longer follow-up (with all except 1 case occurring more than 4 years after PRRT treatment) or to the addition of concurrent chemotherapy. Lutetium-177-Octreotate PRRT remains an efficacious and well tolerated treatment in long-term follow-up. For clinicians deciding on the timing of PRRT for individual patients, the 6.7% long-term risk of MDS/leukemia needs to be balanced against the 21% PFS at 10 years.
Cancer (Hoboken, NJ, United States) published new progress about Acute myeloid leukemia. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, HPLC of Formula: 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics